Bioceros offers cell line generation services related to the preclinical development of monoclonal antibodies and generation of GMP-ready protein producing cell lines. They have a toolbox to modify product characteristics according to customer needs, and (bio-)analytics including mass spectrometry.

Together with the other divisions of the Polpharma Group, which has acquired Bioceros, they offer a completely integrated program from DNA to the drug product.

Company: Bioceros
Fund: I
Status: Realized
Team member: Michel Briejer
Technology: Therapeutics
Website: bioceros.com